Run M1 CRC Challenge Assessment (SAMPLE 3)

Your name will be kept confidential to participants and any feedback you provide as an assessor will be forwarded anonymously.

Patient JF is a 66 year old man with advanced colorectal carcinoma and peritoneal carcinomatosis.  He has received 6 cycles of FOLFIRI + panitumumab; however his oncologist notes worsening of his ascites and CT scans show definitive disease progression on therapy.  A tumor sample is referred in for molecular testing to inform his next line of therapy.

DOB: March 1, 1956 MRN: 34567

Lab 902 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 903 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 904 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 905 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 906 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 907 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 908 SAMPLE 3

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No

Lab 901 SAMPLE 3

Results were not submitted in time for assessment. Complete the questions below to the best of your abilities.

REFERENCE RESULTS: MSS (MMR intact), BRAFV600E
Yes
No
N/A
Resistance to anti-EGFR monoclonal antibody therapy
Yes
No
N/A
Sensitivity to BRAF TKI + anti-EGFR mAb
Yes
No
N/A